Botanix Pharmaceuticals
Botanix Pharmaceuticals is an Australian clinical dermatology company focused on developing and commercializing innovative treatments for common skin diseases. Their lead product candidate is Sofdra, a potential treatment for primary axillary hyperhidrosis, and they are also developing other products for acne and atopic dermatitis.
Short position
Botanix Pharmaceuticals (ASX:BOT) has 0.64% of its shares on issue reported as short positions as of 5 Oct 2026, or about 17,619,596 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.42 percentage points. Its highest recorded short interest was 5.23% in July 2025. BOT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Botanix Pharmaceuticals (BOT) short interest history
BOT Short Interest History
- 30-day change
- +0.02pp
- 90-day change
- +0.42pp
- 1-year change
- -3.09pp
- All-time high
- 5.23% (July 2025)
- All-time low
- 0.00% (April 2024)
Is BOT heavily shorted?
Not especially: 0.64% short interest is modest by ASX standards, ranking #300 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has BOT's short interest changed recently?
Over the past 30 days Botanix Pharmaceuticals's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.64% of shares on issue.
What is the highest BOT's short interest has been?
Since 2018, Botanix Pharmaceuticals's short interest peaked at 5.23% in July 2025 and bottomed at 0.00% in April 2024.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2018. See our methodology.